Oruka Therapeutics, Inc. (ORKA)Healthcare | Biotechnology | Menlo Park, United States | NasdaqGM
84.56 USD
-2.23
(-2.569%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 84.56 |
Hot Take ↕ | July 11, 2026, 3:23 a.m. EDT
Oruka presents a stark dichotomy: technically, the stock is rallying hard off its multi-year lows, trading well above its 50- and 200-day averages, yet fundamentally, it remains a cash-burning biotech with a nine-year price trajectory that has erased nearly 98% of shareholder value. While analysts project a strong buy and the balance sheet holds ample cash reserves, the relentless negative earnings and free cash flow suggest the current rally is priced on a turnaround narrative rather than proven execution. Recent insider selling adds a layer of skepticism to the bullish technicals, making this a high-risk momentum play rather than a stable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.318085 |
| MSTL | 0.429777 |
| AutoARIMA | 0.439775 |
| AutoETS | 0.447834 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 8.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.157 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2024-08-28 |
| Debt to Equity Ratio | 0.371 |
| Market Cap | 5,099,991,040 |
| Forward P/E | -33.93 |
| Website | https://orukatx.com |
As of July 11, 2026, 3:23 a.m. EDT: Speculators are positioning defensively with heavy put open interest concentrated at lower strikes (40 to 75), indicating a fear of further downside. Call activity is clustered near the current price (90 to 95) with some speculative flow at higher strikes (110), suggesting a potential rebound attempt. Implied volatility remains elevated across expirations, reflecting significant uncertainty.
| Date | Dividend | Yield % |
|---|---|---|
| 2024-08-29 | 19.356 | 64.52 |
| Attribute | Value |
|---|---|
| 52 Week Change | 4.904082 |
| Address1 | 855 Oak Grove Avenue |
| Address2 | Suite 100 |
| All Time High | 75,932,640.0 |
| All Time Low | 5.49 |
| Ask | 106.9 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,012,080 |
| Average Daily Volume3 Month | 1,820,344 |
| Average Volume | 1,820,344 |
| Average Volume10Days | 2,012,080 |
| Bid | 60.74 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 9.643 |
| City | Menlo Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 84.56 |
| Current Ratio | 23.763 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 85.82 |
| Day Low | 82.53 |
| Debt To Equity | 0.371 |
| Display Name | Oruka Therapeutics |
| Dividend Date | 1,724,803,200 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,392,000 |
| Earnings Timestamp Start | 1,786,392,000 |
| Ebitda | -133,289,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -35.381 |
| Enterprise Value | 4,715,900,416 |
| Eps Current Year | -2.03882 |
| Eps Forward | -2.49214 |
| Eps Trailing Twelve Months | -1.93 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 70.1208 |
| Fifty Day Average Change | 14.439201 |
| Fifty Day Average Change Percent | 0.20591895 |
| Fifty Two Week Change Percent | 490.40817 |
| Fifty Two Week High | 97.78 |
| Fifty Two Week High Change | -13.220001 |
| Fifty Two Week High Change Percent | -0.13520148 |
| Fifty Two Week Low | 12.84 |
| Fifty Two Week Low Change | 71.72 |
| Fifty Two Week Low Change Percent | 5.58567 |
| Fifty Two Week Range | 12.84 - 97.78 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 871,047,000,000 |
| Float Shares | 51,086,159 |
| Forward Eps | -2.49214 |
| Forward P E | -33.930676 |
| Free Cashflow | -56,126,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 68 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0123000005 |
| Held Percent Institutions | 0.89696 |
| Implied Shares Outstanding | 60,312,101 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://phx.corporate-ir.net/phoenix.zhtml?c=109749&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,724,889,600 |
| Last Dividend Value | 19.356 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,725,321,600 |
| Last Split Factor | 1:12 |
| Long Business Summary | Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. |
| Long Name | Oruka Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,099,991,040 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1877171755 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -94,190,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,234,487,245 |
| Number Of Analyst Opinions | 12 |
| Open | 84.94 |
| Operating Cashflow | -90,919,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 606 7910 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 84.56 |
| Post Market Time | 1,783,981,119 |
| Previous Close | 86.79 |
| Price Eps Current Year | -41.474968 |
| Price Hint | 2 |
| Price To Book | 8.769055 |
| Profit Margins | 0.0 |
| Quick Ratio | 23.377 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.15385 |
| Region | US |
| Regular Market Change | -2.23 |
| Regular Market Change Percent | -2.56942 |
| Regular Market Day High | 85.82 |
| Regular Market Day Low | 82.53 |
| Regular Market Day Range | 82.53 - 85.82 |
| Regular Market Open | 84.94 |
| Regular Market Previous Close | 86.79 |
| Regular Market Price | 84.56 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 728,491 |
| Return On Assets | -0.18915 |
| Return On Equity | -0.27306998 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 60,312,101 |
| Shares Percent Shares Out | 0.1519 |
| Shares Short | 9,160,848 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,373,113 |
| Short Name | Oruka Therapeutics, Inc. |
| Short Percent Of Float | 0.2315 |
| Short Ratio | 5.59 |
| Source Interval | 15 |
| State | CA |
| Symbol | ORKA |
| Target High Price | 200.0 |
| Target Low Price | 102.0 |
| Target Mean Price | 144.66667 |
| Target Median Price | 141.5 |
| Total Cash | 388,828,992 |
| Total Cash Per Share | 6.447 |
| Total Debt | 1,807,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 43.6967 |
| Two Hundred Day Average Change | 40.863297 |
| Two Hundred Day Average Change Percent | 0.9351575 |
| Type Disp | Equity |
| Volume | 728,491 |
| Website | https://orukatx.com |
| Zip | 94,025 |